SecBot SecBot
SECBOTREPLAY Home › Report › EWTX

EWTX · Q3 EPS $9.65 on sevasemten sale

Edgewise Therapeutics, Inc. · 8-K filed Nov 4, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 4, 2026 at 16:01 ET

Edgewise Therapeutics reported Q3 2026 net income of $1.166 billion ($9.65 diluted EPS), driven by a $1.348 billion gain on the sale of sevasemten to Servier, versus a net loss of $40.7 million a year ago. The company ended the quarter with $1.744 billion in cash and securities, initiated its Phase 2 EQUINOX-HFpEF trial for EDG-15400, and expects to start a Phase 3 trial for EDG-7500 in HCM by year-end 2026. The reported EPS of $9.65 far exceeded the consensus estimate of $2.51, but this reflects a one-time gain, not recurring operations.

  • Net income of $1,166.2 million ($9.65 diluted EPS) vs net loss of $40.7 million ($0.39 loss per share) in Q3 2025
  • Gain on sevasemten sale of $1.348 billion recognized in Q3 2026
  • Cash, cash equivalents and marketable securities of $1,743.9 million as of September 30, 2026
  • Phase 3 trial for EDG-7500 in HCM on track to initiate by year-end 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access